Bannayan–Riley–Ruvalcaba Syndrome (BRRS) — Comprehensive Research Report

Prepared: 2026-08-03 · Target: kb/disorders/Bannayan-Riley-Ruvalcaba_Syndrome.yaml · Category: Mendelian (autosomal dominant, tumor-predisposition / overgrowth)

⚠️ Curator preflight — read this before you copy anything into YAML

Three things will bite you on this entry, so let's get them out of the way first.

1. Named Entity Confusion risk here is HIGH. BRRS is a triple eponym collision that got merged in the early 1990s — Bannayan–Zonana syndrome, Riley–Smith syndrome, and Ruvalcaba–Myhre–Smith syndrome were three separately-named conditions that turned out to be one thing. Several databases (NORD included) still file it under ruvalcaba-syndrome. Adjacent traps: Riley–Day syndrome (familial dysautonomia, IKBKAP/ELP1 — completely unrelated), Ruvalcaba syndrome (a distinct skeletal-dysplasia eponym), and Cowden syndrome (MONDO:0016063, OMIM:158350), which is the same gene and arguably the same disease but a different KB entity. A deep-research report on "Bannayan syndrome" that talks mostly about breast/thyroid cancer surveillance in adults has probably drifted into Cowden. Run just preflight-dr <report> MONDO:0007924 and expect the canonical gene to be PTEN.

2. Every ontology ID below is a candidate. My local OAK install in this worktree is broken (the Python 3.14 pyhornedowl failure), so I could not verify a single HP/GO/CL/UBERON/CHEBI/NCIT identifier against the authority. Treat the term tables as leads and run just validate-terms before committing. I've flagged the ones I'm least sure about.

3. Quotes marked "verbatim" came from the Europe PMC abstractText field, which is the real abstract — but the reference validator is the arbiter, not me. Run just fetch-reference PMID:xxxxx then just validate-references for each one. Two abstracts I could not retrieve (Marsh 1997 Nat Genet is a letter with no abstract at all; Parisi 2001 has no abstractText in Europe PMC) — do not invent snippets for those.

1. Disease Information

Overview

Bannayan–Riley–Ruvalcaba syndrome is a rare congenital overgrowth and hamartoma disorder, present from birth, defined by the combination of macrocephaly, hamartomatous intestinal polyposis, lipomas, vascular malformations, and pigmented macules of the glans penis (genital lentiginosis), frequently with developmental delay and/or autism spectrum disorder. It is one of the historical clinical presentations now unified under the molecular umbrella of PTEN hamartoma tumor syndrome (PHTS).

The single most consequential fact for a knowledge base: BRRS and Cowden syndrome are, mechanistically, the same disease. Marsh et al. established this in 1999 and Lachlan et al. confirmed it clinically in 2007; GeneReviews now states flatly that the historical phenotypes "represent a unified disease spectrum under the PHTS designation" and that PHTS has no clinical diagnostic criteria of its own — molecular confirmation of a germline PTEN variant is the diagnosis.

Verbatim (PMID:10400993, Marsh et al. 1999, Hum Mol Genet 8:1461–72): "Thus, PTEN mutation-positive CS and BRR may be different presentations of a single syndrome and, hence, both should receive equal attention with respect to cancer surveillance."

BRRS is best understood as the pediatric-onset end of the PHTS spectrum (overgrowth, lipomas, polyps, neurodevelopment) and Cowden syndrome as the adult-onset end (mucocutaneous lesions, breast/thyroid/endometrial cancer), with the same gene and age-related penetrance connecting them.

Identifiers

Synonyms and alternative names

From the MONDO record: BRRS, Bannayan syndrome, Bannayan–Zonana syndrome (BZS), Riley–Smith syndrome, Myhre–Riley–Smith syndrome, Ruvalcaba–Myhre–Smith syndrome (RMSS), "macrocephaly with multiple lipomas and hemangiomas." Also encountered: macrocephaly–multiple lipomas–hemangiomata syndrome, Bannayan–Ruvalcaba–Riley syndrome.

Nature of the evidence base

Overwhelmingly aggregated disease-level and case-level literature, not EHR-derived. The definitive BRRS-specific evidence is a 2024 systematic review of 83 published pediatric cases from 33 articles (PMID:39256443) — all case reports and small series, which the authors explicitly flag as high risk of bias. The large quantitative datasets (cancer risk, GI phenotype) all come from Cowden-ascertained PHTS cohorts (Cleveland Clinic, Dutch/European registries) and must be attributed as PHTS-wide rather than BRRS-specific. A very recent unbiased population signal exists (All of Us / UK Biobank) but is still a preprint as of December 2025.

2. Etiology

Primary cause

Heterozygous germline loss-of-function variants in PTEN (phosphatase and tensin homolog), at 10q23.31. PTEN is a haploinsufficient tumor suppressor; loss of its lipid-phosphatase activity releases the brake on PI3K–AKT–mTOR signaling.

Detection rate in BRRS specifically: ~60% in the classic ascertained series.

Verbatim (PMID:10400993): "In this study, constitutive DNA samples from 43 BRR individuals comprising 16 sporadic and 27 familial cases, 11 of which were families with both CS and BRR, were screened for PTEN mutations. Mutations were identified in 26 of 43 (60%) BRR cases."

The 2024 pediatric systematic review reports a much higher rate — 75/83 (90%) — but that reflects modern ascertainment (patients are increasingly defined by having the variant). The earlier Marsh 1998 series found 4/7 (57%) in Bannayan–Zonana families.

Verbatim (PMID:9467011, Marsh et al. 1998, Hum Mol Genet 7:507–15): "Germline PTEN mutations were identified in four of seven (57%) BZS families studied. Interestingly, none of these mutations was observed in the PTPase core motif."

That last clause is a real, curatable genotype–phenotype observation: BRRS-associated variants were not found in the phosphatase core motif, whereas Cowden variants clustered there (43% of CD mutations in exon 5).

Genetic risk factors beyond PTEN

TTN (titin) — candidate second gene for PTEN-wildtype BRRS. This is the most important non-PTEN finding and is BRRS-specific rather than Cowden-derived.

Verbatim (PMID:29263846, Yehia, Ni & Eng 2017, npj Genom Med 2:37): "We exome-sequenced 35 unrelated PTEN-wildtype patients with classic presentation of BRRS and identified TTN germline missense variants in 12/35 (34%) patients... Rare TTN variants (MAF ≤ 0.0001) are enriched in classic BRRS patients compared to BRRS-like (OR = 2.7, 95% CI 1.21-5.94, p = 1.6 × 10⁻²) and multiple population controls (OR = 2.2, 95% CI 1.01-4.20, p = 4.7 × 10⁻²)."

Functional support: CRISPR-edited cells carrying the I-band variant p.Cys5096Arg showed "increased growth and lack of contact inhibition... associated with increased levels of or phosphorylation of focal adhesion kinase (FAK)." The authors propose BRRS may "join the growing list of Titinopathies." Curation note: this is a candidate gene — use relationship_type: SUSCEPTIBILITY or MODIFIER, not causal, and tag evidence_source: IN_VITRO for the FAK/CRISPR arm.

Other PTEN-wildtype routes (established in Cowden-like, extrapolate cautiously to BRRS): - KLLN/KILLIN germline promoter hypermethylation — 37% of 123 PTEN-mutation-negative Cowden/Cowden-like patients; downregulates KILLIN ~250-fold with normal PTEN transcription (Bennett, Mester & Eng 2010, JAMA 304:2724–31, PMID:21177507). Associated with ~3-fold higher breast cancer and >2-fold higher renal cancer prevalence than germline PTEN variants. Assigned OMIM #615107 (Cowden syndrome 4). - SDHB/*SDHD germline variants — 3 SDHB and 7 SDHD among 74 PTEN-negative Cowden-like individuals with elevated MnSOD (Ni et al. 2008, Am J Hum Genet 83:261–8, PMID:18678321). - Additional unexpected cancer-predisposition gene variants in PTEN-wildtype CS/BRRS (Yehia et al. 2018, PLoS Genet*).

Environmental risk factors

None established. BRRS is a monogenic Mendelian disorder with no documented environmental cause, no infectious trigger, and no lifestyle risk factor for the syndrome itself. This is a legitimate "not applicable" for the KB — do not fabricate.

Downstream cancer risk in carriers plausibly interacts with generic exposures (UV for the ~6% melanoma risk; diagnostic radiation given the tumor predisposition), but I found no BRRS/PHTS-specific gene–environment interaction study. Age is the dominant non-genetic modifier of expression — penetrance is strongly age-related, which is the reason BRRS and Cowden look like different diseases at different life stages.

Protective factors

No genetic protective variants or modifier alleles are documented. No dietary or lifestyle protective factor has been demonstrated. The only genuinely "protective" intervention is surveillance-based early detection, which is secondary prevention, not risk reduction.

Gene–environment interactions

Not characterized for BRRS. Report this as a knowledge gap — a discussions entry with kind: KNOWLEDGE_GAP is the honest treatment.

3. Phenotypes

BRRS-specific frequencies (best available source)

From the 2024 systematic review of 83 pediatric BRRS patients (PMID:39256443, Kapačinskaitė et al., Sci Rep 14, doi:10.1038/s41598-024-71991-2). These are frequencies among published pediatric case reports — publication bias is severe, so use qualitative FrequencyEnum bands rather than curating the exact percentages as population frequencies. Per docs/frequency-evidence-guidelines.md, the mapping below is my suggestion; when a number is soft, omit frequency: entirely.

Verbatim (PMID:39256443): "A total of 83 pediatric patients with BRRS were identified. The most common clinical findings were macrocephaly (77%) and developmental disorders (63%)."

Demographics from the same review: male predominance 60/83 (72%) — almost certainly an ascertainment artifact, since genital lentiginosis is a male-only diagnostic clue; median age 8 years; de novo variants in up to 48%.

Additional features (established in the older literature, frequencies less firm)

Neonatal macrosomia / large birth weight; accelerated linear growth in early childhood; muscular hypotonia and proximal myopathy (a genuinely BRRS-flavored feature, sometimes with lipid storage on muscle biopsy); joint hyperextensibility; pectus excavatum; scoliosis; café-au-lait macules; frontal bossing and dolichocephaly; downslanting palpebral fissures; Hashimoto thyroiditis (Gorlin et al. 1992, Am J Med Genet 44:307–14, PMID:1336932 — expanded the BRRS phenotype to include Hashimoto thyroiditis, present in 7 of their cases); high-arched palate; enlarged perivascular Virchow–Robin spaces on brain MRI.

Phenotype characteristics

• Onset: congenital / neonatal for macrocephaly and macrosomia; infancy–early childhood for lipomas, vascular anomalies, and developmental concerns; peripubertal/adolescent (age ~10+) for genital lentiginosis; adult for the epithelial cancers.
• Severity: highly variable, even within a single family carrying the identical variant. Lachlan et al. (2007, J Med Genet 44:579–85) concluded BRRS and CS are "one condition with variable expression and age-related penetrance" and argued it is "not helpful to split PTEN-related disorders into separate clinical syndromes."
• Progression: the overgrowth features are largely stable/static after early childhood (macrocephaly does not progress; some lipomas enlarge). The tumor-predisposition component is progressive with age — new lesions and malignancies accrue lifelong. Vascular anomalies (PTEN hamartoma of soft tissue) are typically progressive and symptomatic, presenting with pain and swelling.
• Quality-of-life impact: driven mostly by (a) neurodevelopment — intellectual disability, ASD, attention and processing-speed deficits; (b) pain and functional impairment from intramuscular vascular/soft-tissue hamartomas (one case in the Kurek series required amputation); (c) the psychological burden of lifelong cancer surveillance. I found no BRRS-specific EQ-5D/SF-36/PROMIS data — this is a real gap; the sirolimus vascular-anomaly experience reports "significant improvement in patient quality of life" without a validated instrument. Do not curate a QoL number.

Neurodevelopmental detail

PTEN is now recognized as one of the commonest monogenic causes of ASD with macrocephaly (~10% of ASD-plus-macrocephaly cases). GeneReviews: neurodevelopmental disorders in ~35% of children with PHTS; epilepsy 6–17% vs ~1% general population. Frazier et al. 2015 (Mol Psychiatry, PMID:25288137) found PTEN-ASD specifically associated with prominent white-matter abnormalities and "strong reductions in processing speed and working memory," with white-matter abnormality mediating the relationship between PTEN protein level and full-scale IQ. A 2024 systematic review of PHTS neurology (Dhawan, Baitamouni, Liu & Eng, Neurology 103(7):e209844, PMID:39250745) screened 1,996 articles and included 90 — but 54% were case reports, so the neurological evidence base is thin.

4. Genetic / Molecular Information

Causal gene

PTEN, 10q23.31, 9 exons, encoding a 403-amino-acid dual-specificity protein/lipid phosphatase. HGNC hgnc:9588 (note this repo's lowercase-prefix convention). OMIM *601728. UniProt P60484. A processed pseudogene, PTENP1 on chromosome 9, cross-amplifies during PCR and must be designed around — a practical testing caveat worth capturing.

Variant spectrum

• Types: missense, nonsense, frameshift, splice-site, small indels, and whole-exon to whole-gene deletions. All classes are represented.
• Exon 5 hotspot: "Nearly 40%" of PHTS variants fall in exon 5, which encodes the phosphatase (PTPase) core motif (HCXXGXXR, residues ~123–130). Marsh 1998 found 13/30 (43%) of Cowden variants in exon 5, with 7/30 (23%) inside the core motif itself — and notably none of the Bannayan–Zonana variants in the core motif.
• Recurrent variants: c.388C>T (p.Arg130Ter), c.697C>T (p.Arg233Ter), c.1003C>T (p.Arg335Ter). R233X was seen in two unrelated Cowden families and one BZS family in the Marsh 1998 series — direct evidence for allelism.
• Detection method yield (GeneReviews): coding-region sequencing ≤80%; deletion/duplication analysis 3–11%; promoter-region sequencing ~10% (do not skip the promoter).
• Origin: germline for the syndrome; de novo in up to 48% of BRRS cases per the 2024 review — so a negative family history is common and does not argue against the diagnosis. Somatic PTEN loss is separately one of the most frequent events in sporadic cancer (glioblastoma, endometrial, prostate) — mechanistically informative but not part of the BRRS entry.
• Population frequency: PTEN loss-of-function variants are extremely rare in gnomAD; the gene is strongly LoF-constrained. Recent unbiased biobank data suggest carriers are far commoner than the clinic-based estimate: an All of Us analysis found 55 P/LP carriers among 414,830 participants (~1 in 7,500), ~26-fold above historical estimates, with 43.5% having a cancer diagnosis (median age at first cancer 48 y). ⚠️ This is a medRxiv preprint (PMID:41480035, Dec 2025) — cite as preliminary, evidence_source: HUMAN_CLINICAL but flag preprint status. GeneReviews gives ~1 in 9,000 (All of Us) to 1 in 13,000 (UK Biobank).
• Functional consequence: loss of function / haploinsufficiency is the dominant mechanism. Some missense alleles act as dominant negatives (the PTEN dimer means a catalytically dead monomer can poison the wild-type partner) — mechanistically important and worth a distinct pathophysiology node. Missense variants generally associate with milder phenotypes than truncating variants.

Genotype–phenotype correlations

From Marsh 1999 (BRRS-specific):

Verbatim (PMID:10400993): "Genotype-phenotype analyses within the BRR group suggested a number of correlations, including the association of PTEN mutation and cancer or breast fibroadenoma in any given CS, BRR or BRR/CS overlap family (P = 0.014), and, in particular, truncating mutations were associated with the presence of cancer and breast fibroadenoma in a given family (P = 0.024). Additionally, the presence of lipomas was correlated with the presence of PTEN mutation in BRR patients (P = 0.028)."

From Tan 2012 and GeneReviews (PHTS-wide): promoter variants → breast cancer; nonsense variants → colorectal cancer; frameshift variants overrepresented in thyroid cancer; missense variants overrepresented in ASD. Caveat for curation: these are cohort-level associations from ascertained series and should be curated with the association language, not as deterministic rules.

Verbatim (PMID:22252256): "Promoter mutations were associated with breast cancer, whereas colorectal cancer was associated with nonsense mutations."

Modifier genes

Not formally established. TTN (above) is a candidate contributing/modifying locus in PTEN-wildtype disease. Second somatic hits in PTEN and downstream PI3K-pathway lesions modulate lesion-level behavior but are not germline modifiers.

Epigenetics

• Germline KLLN promoter hypermethylation (see §2) — a bona fide germline epigenetic etiology within the PHTS/Cowden-like spectrum, and one of the more elegant examples in human genetics: PTEN and KLLN share a bidirectional promoter, and the methylation silences KILLIN without touching PTEN transcription.
• Somatic PTEN promoter methylation in tumors is a common second-hit mechanism.

Chromosomal abnormalities

Whole-gene and multi-exon PTEN deletions account for 3–11% of cases and are missed by sequencing alone — MLPA or CMA is required to complete the workup. Larger 10q23 contiguous-gene deletions spanning PTEN and BMPR1A produce a severe juvenile-polyposis-plus-BRRS phenotype in infancy and are worth curating as a distinct, more severe presentation.

5. Environmental Information

Not applicable as an etiology. No environmental factor, toxin, radiation exposure, occupational exposure, dietary factor, or infectious agent has been implicated in causing BRRS. There is no NCBI Taxon organism to associate.

The only defensible environmental content is downstream and generic: UV exposure as a modifiable contributor to the melanoma component (lifetime risk up to 6%, earliest reported age 3 years), which is why "sun protection" appears in the parent-education recommendations of the 2024 systematic review. Curate that as prevention guidance, not as an etiologic environmental factor.

6. Mechanism / Pathophysiology

The causal chain, upstream → downstream

Node 1 — Germline PTEN haploinsufficiency (MOLECULAR). One PTEN allele is inactivated in every cell from conception. Because PTEN is dose-sensitive, even 50% protein reduction perturbs signaling; tissue-specific second hits (somatic mutation, LOH, promoter methylation) deepen the loss focally and explain the patchy, hamartomatous distribution of lesions.

Node 2 — Loss of PIP₃ 3-phosphatase activity (MOLECULAR). PTEN's canonical function is dephosphorylating the 3-position of the inositol ring of phosphatidylinositol 3,4,5-trisphosphate (PIP₃), converting it back to PIP₂ — it is the direct antagonist of class I PI3K. Established by Maehama & Dixon 1998 (J Biol Chem 273:13375–8, PMID:9593664), who showed PTEN overexpression reduced insulin-induced PtdIns(3,4,5)P₃ in 293 cells and that purified recombinant PTEN dephosphorylates PIP₃ specifically at the 3-position. Marsh 1999 frames it in disease terms: "PTEN maps to 10q23 and encodes a dual specificity phosphatase, a substrate of which is phosphatidylinositol 3,4,5-triphosphate, a phospholipid in the phosphatidylinositol 3-kinase pathway."

Node 3 — Constitutive PI3K–AKT–mTORC1 pathway activation (CELLULAR). PIP₃ accumulates at the plasma membrane → PH-domain recruitment of AKT and PDK1 → AKT phosphorylation (Thr308/Ser473) → inhibition of TSC1/TSC2 → RHEB-GTP → mTORC1 activation → S6K1/4E-BP1 phosphorylation → increased cap-dependent translation, ribosome biogenesis, and cell mass. In parallel AKT phosphorylates and inactivates FOXO transcription factors, GSK3β, and BAD.

Node 4a — Increased cell growth, proliferation, and survival (CELLULAR). Net effect: increased cell size (not just number), increased proliferation, suppressed apoptosis, suppressed autophagy, loss of contact inhibition.

Node 4b — Cell-size / soma-size enlargement (CELLULAR). This is the specific mechanism behind macrocephaly and neuronal hypertrophy, and it's mTORC1-driven — which is why it is pharmacologically addressable.

Node 5 — Tissue-level hamartomatous overgrowth (TISSUE). Disorganized overgrowth of mature mesenchymal and epithelial elements — the definition of a hamartoma. Produces lipomas, GI polyps, PTEN hamartoma of soft tissue, and cerebellar dysplastic gangliocytoma.

Node 6 — Organism-level manifestations (ORGANISM). Macrocephaly, macrosomia, accelerated linear growth, ASD/DD, and lifelong tumor predisposition.

Parallel / non-canonical arms worth separate nodes

• Protein-phosphatase and phosphatase-independent functions. PTEN also dephosphorylates protein substrates (e.g. FAK) and has scaffolding functions. The BRRS TTN work lands here: the p.Cys5096Arg variant produced "increased growth and lack of contact inhibition phenotype associated with increased levels of or phosphorylation of focal adhesion kinase (FAK)" — a PI3K-independent route to the same overgrowth output. Good candidate for an ALTERNATIVE or EMERGING mechanistic_hypotheses group.
• Nuclear PTEN. PTEN shuttles to the nucleus, where it maintains chromosomal integrity and promotes RAD51-dependent DNA repair, independent of lipid phosphatase activity. Variants disrupting nuclear localization signals segregate with the ASD-predominant phenotype rather than the cancer phenotype (the basis of the Pten^m3m4^ mouse; §15). This is arguably the single most interesting mechanistic split in PHTS: where PTEN is, not just how much there is, determines whether you get autism or cancer. Curate as competing/complementary hypothesis groups.
• Neurodevelopmental arm. PTEN loss in neurons → mTORC1 → increased soma size, exuberant dendritic arborization, aberrant synaptic connectivity, and (per the m3m4 mouse work) microglial activation with excessive synaptic pruning. Downstream: macrocephaly, white-matter abnormality, ASD, epilepsy.
• Vascular arm. PI3K–AKT is a core endothelial/angiogenic pathway; PTEN loss produces the fast-flow vascular anomalies and intramuscular AVM-like lesions. Tan et al. 2007 (J Med Genet 44:594–602) found vascular anomalies in 14/26 (54%) of PTEN carriers, 57% multiple, 85% intramuscular on cross-sectional imaging, and 86% fast-flow.

Cellular processes, cell types, and compartments

Metabolic, immune, and tissue-damage dimensions

• Metabolic: AKT–mTORC1 activation shifts cells toward anabolic metabolism (glucose uptake, glycolysis, lipogenesis, protein synthesis). PTEN-carrier humans and Pten⁺/⁻ mice show enhanced insulin sensitivity — a notable, counterintuitive metabolic phenotype of the syndrome.
• Immune: no autoimmunity is intrinsic to the mechanism, except that Hashimoto thyroiditis is overrepresented (Gorlin 1992: 7 cases) — mechanism unresolved, a legitimate knowledge gap. Microglial (innate CNS immune) activation is a key finding in the m3m4 mouse.
• Tissue damage: BRRS is a disease of disorganized overgrowth, not of degeneration. There is no oxidative-stress/ischemia/fibrosis/necrosis core mechanism. The exceptions are secondary: mass effect and compression from lipomas and soft-tissue hamartomas, GI bleeding and intussusception from polyps, and high-output/steal physiology from fast-flow vascular lesions.

Molecular profiling

BRRS-specific omics are essentially absent. What exists is from PHTS/model systems: transcriptome and (phospho)proteome characterization of the cytoplasmic-predominant Pten^m3m4^ brain (npj Genom Med 2021), alternative-splicing landscape of the same model (Transl Psychiatry 2020), and a neural transcriptome study linking constitutional Pten dysfunction to idiopathic human ASD (PMID:25754085). Cortical transcriptomics in m3m4 showed upregulation of myeloid cell activation, myeloid cell migration, and phagocytosis pathways. No BRRS metabolomics, lipidomics, spatial transcriptomics, or single-cell atlas exists that I could find. Curate as gaps.

7. Anatomical Structures Affected

Organ level

Primary (directly affected by the germline lesion): - Brain (UBERON:0000955) — megalencephaly, enlarged perivascular spaces, white-matter abnormality, cortical malformations; cerebellum (UBERON:0002037) for dysplastic gangliocytoma / Lhermitte–Duclos disease - Skin and subcutis (UBERON:0002097) — lipomas, hemangiomas, café-au-lait macules, acral keratoses - Penis / external genitalia (UBERON:0000989) — pigmented macules of the glans, the BRRS-defining sign - Gastrointestinal tract — colon (UBERON:0001155), also ileum, duodenum, stomach, esophagus. Heald 2010 documented polyps throughout: "There were one to innumerable polyps in the colorectum, ileum, duodenum, stomach, and/or esophagus, with 24 subjects having both upper and lower GI polyps." - Skeletal muscle (UBERON:0001134) — intramuscular PTEN hamartoma of soft tissue; proximal myopathy - Adipose tissue (UBERON:0001013) — lipomatous overgrowth - Thyroid gland (UBERON:0002046) — goiter, nodules, Hashimoto thyroiditis, differentiated carcinoma - Blood vessels (UBERON:0001981) — fast-flow malformations, AVMs

Secondary / later-emerging (the PHTS cancer spectrum): breast (UBERON:0000310), endometrium (UBERON:0001295), kidney (UBERON:0002113), skin (melanoma), colon (carcinoma).

Body systems: nervous, integumentary, digestive, endocrine, musculoskeletal, cardiovascular (vascular malformations), reproductive.

Tissue, cell, and subcellular level

Fundamentally a disease of mesenchymal + epithelial tissues in combination. Kurek's definition of PTEN hamartoma of soft tissue is the clearest tissue-level statement available:

Verbatim (PMID:22446940, Kurek et al. 2012, Am J Surg Pathol 36:671–87): "We designate this disorganized overgrowth of essentially mesenchymal elements as PTEN hamartoma of soft tissue."

Its components, per the same abstract: "(1) a variable admixture of mature adipocytic and dense and/or myxoid fibrous tissues (50% to 90% of surface area); (2) a vascular component (10% to 50% of surface area)... (3) lymphoid follicles (50%); (4) foci of bone (20%); and (5) hypertrophic nerves with 'onion bulb' proliferation of periaxonal spindled cells (9%)."

Subcellular: plasma membrane (PIP₃ pool, PTEN's site of action), cytosol, and nucleus — with the nuclear/cytoplasmic partition being mechanistically load-bearing (§6).

Lateralization: lesions are multifocal and asymmetric, not systematically lateralized. Kurek: lesions "most often located in the lower extremity," 20% multifocal, occasionally involving contiguous muscles. Macrocephaly is symmetric.

8. Temporal Development

• Onset: congenital. Macrocephaly is present at birth or emerges in the first two years — "nearly all children by age 2" per the German pediatric guideline. Neonatal macrosomia is common. Onset pattern is insidious/chronic, not acute.
• Lesion timing: Kurek — soft-tissue hamartomas "manifested by 15 years of age, normally with pain and swelling." Genital lentiginosis typically appears around/after puberty, which is why it is a poor sign in toddlers. GI polyps present in ~25–30% of pediatric cases (GeneReviews) but 93% of endoscoped adult carriers.
• Stages: there is no formal staging system. A useful three-phase framing for the KB: (i) congenital/infantile overgrowth phase (macrocephaly, macrosomia, hypotonia, early lipomas/vascular lesions); (ii) childhood neurodevelopmental phase (DD, ASD, epilepsy) with emerging polyps and thyroid nodules; (iii) adult neoplastic phase (breast, thyroid, endometrial, renal, colorectal cancer, melanoma).
• Progression rate: slow and variable. The overgrowth features are largely static; the neoplastic risk is cumulative and age-dependent.
• Course: chronic, lifelong, progressive with respect to tumor risk. Not relapsing-remitting, not episodic. No spontaneous remission of the syndrome. Individual lesions may regress with mTOR-inhibitor therapy (see §12).
• Critical periods: early childhood for neurodevelopmental intervention; age 10–12 for the start of thyroid surveillance (thyroid cancer reported as young as age 4–7); age ~30 for breast surveillance; age 35 for colonoscopy. Genetic diagnosis at any age is the intervention that unlocks all the rest.

9. Inheritance and Population

Epidemiology

• Prevalence: unknown/not documented. Orphanet does not assign a prevalence class to ORPHA:109. A widely circulated figure of ~1 per 200,000 appears in secondary sources without a strong primary citation — do not curate it as a sourced prevalence; use prevalence_class: NOT_YET_DOCUMENTED or ULTRA_RARE with measure_type: UNKNOWN.
• The molecularly-defined denominator is far larger than the clinically-defined one. GeneReviews cites ~1 in 9,000 (All of Us) to 1 in 13,000 (UK Biobank) for germline PTEN P/LP carriers; the 2025 All of Us preprint reports 1 in 7,500 (55/414,830), ~26-fold above historical estimates. These are PHTS-wide, not BRRS, and describe carriers, not diagnosed patients. If you curate them, do it on a PHTS/Cowden entry or with an explicit note; measure_type: CARRIER_FREQUENCY is arguably the honest classification.
• Incidence: no reliable estimate exists.

Inheritance

• Pattern: autosomal dominant (HP:0000006). PTEN is MONDO:0007924's canonical causal gene.
• De novo rate: up to 48% of BRRS cases (2024 systematic review) — high, consistent with a severe pediatric-onset presentation.
• Penetrance: essentially complete for some feature (macrocephaly is near-obligate) but strongly age-related and organ-specific for the tumor phenotypes. Unbiased biobank data suggest penetrance is considerably lower than clinic-ascertained estimates — a live and important controversy. Curate the clinic-based lifetime risks with an explicit ascertainment caveat.
• Expressivity: markedly variable, including within families sharing an identical variant. This is the central clinical-genetics message of Lachlan 2007.
• Anticipation: not a feature (no repeat expansion mechanism).
• Germline mosaicism: reported in PTEN and relevant to recurrence counseling in apparently-de-novo families, but rare and not well quantified. Somatic mosaicism is a recognized cause of segmental/atypical presentations and of negative blood-based testing in a clinically convincing patient — this matters for diagnostics.
• Founder effects / consanguinity / carrier frequency: none — irrelevant for a dominant de-novo-prone condition. No population-specific founder variant is described.

Population demographics

• Ethnic/geographic: no population is over-represented; cases are reported worldwide with no endemic distribution.
• Sex ratio: published pediatric BRRS cases run ~72% male (60/83), but this is very likely ascertainment bias from the male-specific genital-lentiginosis sign. The underlying autosomal-dominant inheritance predicts 1:1. Curate the 1:1 expectation and note the reporting skew.
• Age distribution: BRRS as a label is applied predominantly in childhood (median age 8 in the review); the same genotype in adults is usually labeled Cowden syndrome.

10. Diagnostics

Clinical evaluation

• Occipitofrontal circumference — the highest-yield single measurement; macrocephaly is often >5 SD above mean.
• Genital examination in males for pigmented macules of the glans penis (75% of male cases) — pathognomonic-adjacent and free.
• Dermatologic exam for lipomas, hemangiomas, café-au-lait macules, trichilemmomas/acral keratoses (the latter more Cowden-flavored).
• Developmental/neurobehavioral assessment, including formal ASD evaluation.

Imaging and functional testing

• Brain MRI — megalencephaly, enlarged Virchow–Robin spaces, white-matter changes; the cerebellar "tiger-striped" appearance of Lhermitte–Duclos disease. A dedicated BRRS MRI series exists (Bhargava et al., AJNR 35:402, PMID:23907246).
• MRI for soft-tissue/vascular lesions — Kurek: "an infiltrative soft tissue lesion involving the muscle, fascia, and subcutis with frequently enlarged, serpiginous vessels, small arteriovenous fistulae with disproportionately dilated draining veins, and a prominent adipocytic component." Distinguishing PHOST from a true AVM matters because it changes management.
• Thyroid ultrasound — the pediatric surveillance workhorse.
• Esophagogastroduodenoscopy + colonoscopy — mixed polyposis, upper and lower.
• EEG where seizures are suspected (epilepsy 6–17%).

Biopsy and pathology

• GI polyps in PHTS are a mixed polyposis — this is a frequent diagnostic pitfall, because people expect pure hamartomas. Heald 2010: "Of the 64, half had hyperplastic polyps" and the conclusion — "PTEN-associated CS should be considered a mixed polyp syndrome, with hyperplastic polyps most prevalent, with a risk of early onset colorectal cancer." Hamartomatous, ganglioneuromatous, juvenile, inflammatory, hyperplastic, and adenomatous polyps all occur.
• PTEN hamartoma of soft tissue has the distinctive histology quoted in §7, and per Kurek "its identification should prompt a thorough investigation for PHTS" — i.e. the pathologist can make the syndromic diagnosis.
• Immunohistochemistry for PTEN loss in lesional tissue is supportive.

Genetic testing (the definitive test)

Since PHTS has no clinical diagnostic criteria, molecular confirmation is the diagnosis. Recommended approach:

1. Single-gene PTEN testing — full coding sequence plus the promoter region (~10% of variants are promoter). Design around the PTENP1 pseudogene.
2. Deletion/duplication analysis (MLPA) — mandatory adjunct; 3–11% of variants.
3. Multigene hamartomatous-polyposis / hereditary-cancer panel where the phenotype is ambiguous (differentiating from STK11, SMAD4, BMPR1A, AKT1, PIK3CA).
4. Chromosomal microarray — detects the 10q23 contiguous-gene deletions involving PTEN + BMPR1A, and is often the first test in a child presenting with DD/macrocephaly.
5. WES/WGS — reasonable in the undiagnosed-DD pathway; also the route by which TTN was implicated in PTEN-wildtype BRRS.
6. Not applicable: karyotype (too coarse), FISH (superseded by MLPA/CMA), mtDNA testing, repeat-expansion testing.
7. If PTEN-negative but clinically classic: consider KLLN germline methylation testing, SDHB/SDHD, and mosaicism (test lesional tissue, not just blood).

Omics-based diagnostics

Not established for BRRS. No validated RNA-seq, proteomic, metabolomic, epigenomic (other than the KLLN methylation assay), or liquid-biopsy diagnostic exists. A methylated KILLIN/PTEN plasma assay has been explored for thyroid/breast cancer detection but is not a clinical diagnostic for BRRS.

Clinical criteria and differential diagnosis

The International Cowden Consortium operational criteria (and the Cleveland Clinic PTEN risk calculator, Tan et al. 2011) select who to test; they do not diagnose PHTS. Historical BRRS clinical criteria required macrocephaly plus two of: hamartomatous polyps, lipomas, genital lentiginosis.

Differential diagnosis:

Screening of asymptomatic individuals

Cascade testing of at-risk first-degree relatives is the key intervention, and given up-to-48% de novo rates, parental testing is essential for recurrence counseling. There is no newborn screening and no population carrier screening for PTEN. Prenatal/preimplantation testing is technically available once a familial variant is known.

11. Outcome / Prognosis

• Life expectancy: not formally quantified for BRRS. With surveillance, life expectancy is thought to approach normal; the drivers of mortality are the malignancies, not the overgrowth. Do not curate a survival number — I found none that is BRRS-specific and defensible.
• Cancer risk (PHTS-wide, from clinic-ascertained cohorts):

Verbatim (PMID:22252256, Tan et al. 2012, Clin Cancer Res 18:400–7): "Elevated SIRs were found for carcinomas of the breast [25.4, 95% confidence interval (CI), 19.8-32.0], thyroid (51.1, 38.1-67.1), endometrium (42.9, 28.1-62.8), colorectum (10.3, 5.6-17.4), kidney (30.6, 17.8-49.4), and melanoma (8.5, 4.1-15.6). Estimated lifetime risks were, respectively, 85.2% (95% CI, 71.4%-99.1%), 35.2% (19.7%-50.7%), 28.2% (17.1%-39.3%), 9.0% (3.8%-14.1%), 33.6% (10.4%-56.9%), and 6% (1.6%-9.4%)."

GeneReviews gives comparable ranges (breast 85–91%, thyroid 33–35%, endometrial 28–48%, renal 30–35%, colorectal 17%, melanoma up to 6%) plus soft-tissue sarcoma SIR 10.7 (95% CI 3.9–23.7), median age 46. Later European work (Hendricks et al., Clin Genet 2021; JNCI 2023) gives lower estimates — breast 54–76%, endometrial 6–22%, thyroid 9–21% — reflecting less-biased ascertainment. Curate the range with both anchors and an explicit ascertainment caveat; a single point estimate here would be misleading. - Colorectal cancer, early onset: Heald 2010 — "Nine (13%) subjects had colorectal cancer, all younger than the age of 50. The adjusted standardized incidence ratio was 224.1 (95% confidence interval, 109.3-411.3; P < .0001)." - Morbidity and disability: dominated by neurodevelopmental outcome (intellectual disability, ASD, epilepsy) and by pain/functional loss from soft-tissue and vascular lesions — Kurek reported resected specimens 1.2–25 cm, with amputation required in one patient. GI morbidity from bleeding, anemia, intussusception, and repeated polypectomy. - Complications: early-onset colorectal carcinoma; differentiated thyroid carcinoma (reported as young as 4–7 years); Lhermitte–Duclos disease with mass effect/hydrocephalus; hemorrhage and high-output physiology from fast-flow vascular lesions; recurrent surgical morbidity. - Recovery potential: the germline lesion is not reversible. Individual lesions respond to surgery and, partially, to mTOR inhibition. Developmental gains occur with early intervention. Surveillance is the single largest determinant of outcome. - Prognostic factors: variant type (truncating → higher cancer risk per Marsh 1999; promoter → breast; nonsense → colorectal); age; adherence to surveillance; presence and extent of vascular/soft-tissue hamartomas; severity of neurodevelopmental impairment. No validated prognostic biomarker exists.

12. Treatment

There is no disease-modifying or curative therapy. Management is surveillance + symptom-directed intervention + genetic counseling. The 2024 systematic review is blunt about it: "As targeted treatment is still lacking, symptom relief and long-term surveillance remain the main management strategies."

Surgical / interventional (the mainstay)

Per the 2024 review, surgery was the treatment of choice, described in 19 of 33 articles: - Lipoma excision — for pain, disfigurement, compression. treatment_term: NCIT:C15329 Surgical Procedure ⚠️ - Endoscopic polypectomy — for bleeding, obstruction, dysplasia. ⚠️ verify NCIT term for polypectomy - Thyroidectomy — 4 pediatric cases in the review; prophylactic thyroidectomy is debated in PHTS and is not standard, unlike in MEN2. NCIT:C15289-adjacent ⚠️ - Vascular anomaly management — embolization, sclerotherapy, or resection. Because PHOST is not a true AVM, embolization outcomes are less predictable than for classic AVM. - Resection of Lhermitte–Duclos lesions where symptomatic.

Pharmacotherapy — mTOR inhibitors

Mechanistically the obvious move: PTEN loss → mTORC1 hyperactivation → inhibit mTOR. Results so far are mixed, and this nuance must survive into the KB.

Sirolimus (rapamycin) — CHEBI:9168 ⚠️; therapeutic_modality: SMALL_MOLECULE; treatment_term: NCIT:C15986 Pharmacotherapy. - Komiya et al. 2019 (The Oncologist 24:1510, doi:10.1634/theoncologist.2019-0514): first human interventional study in Cowden/PTEN patients; 18 patients, 16 families; 56-day course. Well tolerated; regression of skin and GI lesions by dermoscopy/endoscopy, improved cerebellar function score at 1 month, and suppressed mTOR signaling in surrogate tissue. Pilot-scale — no efficacy claim. - Open-label sirolimus 2 mg daily × 1 year for colon polyposis in PHTS (NCT04094675, Nov 2018 – Jun 2024) — published in Clin Transl Gastroenterol. - Case-level use in pediatric BRRS for AVM: the 2024 review notes one pediatric case, with AVM size reduction and symptom relief within 6 months. - Sirolimus for PHTS vascular anomalies: well tolerated, patient-reported QoL improvement (n=6).

Everolimus — CHEBI:68478 ⚠️. The one properly controlled trial is negative for its primary endpoint: - Srivastava et al. 2022 (Hum Mol Genet 31:3393–404, PMID:35594551): 6-month phase II, randomized, double-blind, placebo-controlled, everolimus 4.5 mg/m², ages 5–45, n=46 (24 everolimus / 22 placebo). Primary neurocognitive composite: no group difference (Cohen's d = −0.10, p = 0.518); GI adverse events significantly more common on everolimus (p < 0.001). - Curate this honestly. An entry that lists "mTOR inhibitors" as treatment for PHTS neurocognitive symptoms without the negative RCT would be misleading. It is a good candidate for an evidence item with supports: REFUTE or PARTIAL.

Targeted / advanced therapeutics

None approved. No gene therapy, gene editing, cell therapy, RNA-based therapy, or immunotherapy exists for BRRS. PI3K/AKT inhibitors are conceptually attractive and used in PIK3CA-related overgrowth (alpelisib) but are not established in PHTS. Do not extrapolate.

Pharmacogenomics

No PHTS-specific pharmacogenomic guidance. Standard CPIC guidance applies to any drugs used for the cancers that arise.

Supportive, rehabilitative, and counseling

• Early intervention, physical therapy (NCIT:C15302), occupational therapy, speech therapy — for hypotonia, motor delay, and language delay. therapeutic_modality: BEHAVIORAL.
• ASD-specific behavioral intervention and educational support.
• Antiseizure medication where epilepsy is present.
• Genetic counseling (NCIT:C15240) — recurrence risk 50% per offspring; parental testing given the high de novo rate; discussion of prenatal/PGT options; cascade testing of relatives.
• Multidisciplinary care is the explicit recommendation of the 2024 review: "periodic multidisciplinary care that should be individualized to fit every patient's needs."

Treatment strategy

Individualized, lesion-directed, and surveillance-anchored. No treatment algorithm or decision tree is standardized. No combination-therapy regimen exists (so regimen_term is not applicable here).

13. Prevention

• Primary prevention: not possible. The disorder is germline and congenital. No vaccination, no modifiable exposure, no risk-factor modification prevents BRRS. The only true primary prevention available is reproductive — preimplantation genetic testing or prenatal diagnosis once a familial variant is identified, which is a family-planning decision requiring genetic counseling, not a public-health intervention.
• Secondary prevention: this is where essentially all the benefit lives. Surveillance recommendations (synthesizing GeneReviews, the 2020 European guideline (Tischkowitz et al., Eur J Hum Genet 28:1387–93, PMC7608293), the 2025 pediatric update (Clin Cancer Res 31(2):234), and the German pediatric guideline):

Yield data exist and are modest but real: thyroid ultrasound surveillance detected DTC in 2/43 (4.65%) of PHTS patients before age 18 in one expertise centre.

• Tertiary prevention: management of polyp burden to prevent CRC; management of vascular lesions to prevent hemorrhage; neurodevelopmental support to maximize function.
• Risk stratification: the Cleveland Clinic PTEN score (Tan et al. 2011) identifies who should be tested; variant type provides coarse organ-risk stratification.
• Immunization, public-health, and environmental interventions: not applicable.

14. Other Species / Natural Disease

• Naturally occurring BRRS in other species: none reported. I found no OMIA entry for a spontaneous PTEN hamartoma syndrome in companion animals or wildlife, and no veterinary breed predisposition. There is no VBO breed to assign.
• Zoonotic potential / cross-species transmission: not applicable — it's a germline genetic disorder.
• PTEN orthologs are deeply conserved, which is what makes the modeling work: mouse Pten (NCBI Gene 19211, NCBITaxon:10090), rat Pten, zebrafish has two paralogs ptena/ptenb (NCBITaxon:7955), Drosophila Pten (NCBITaxon:7227), C. elegans daf-18 (NCBITaxon:6239). The daf-18 connection is a nice piece of comparative biology: the insulin/IGF-1–PI3K–DAF-16/FOXO axis controlling dauer formation and lifespan in worms is the same pathway that, dysregulated in humans, produces hamartomas. Conserved mechanism, wildly different phenotypic readout.
• Comparative pathology: somatic PTEN loss is a recurrent event in spontaneous canine and feline tumors (canine osteosarcoma, melanoma, glioma), making dogs an incidental comparative-oncology resource — but that is somatic tumor biology, not the germline syndrome.

15. Model Organisms

Mouse (NCBITaxon:10090) — the workhorse

Why the m3m4 model matters for this entry: it demonstrates that subcellular mislocalization of PTEN — with normal expression level — is sufficient to produce the neurodevelopmental arm of PHTS. That's a genuine mechanistic dissociation between the ASD phenotype and the cancer phenotype, and it maps directly onto the human genotype–phenotype observation that missense variants are overrepresented in ASD. It is the strongest argument for curating the neurodevelopmental and neoplastic arms as separate pathophysiology branches.

Other systems

• Zebrafish (NCBITaxon:7955): ptena/ptenb double mutants are embryonic lethal with hyperbranched vasculature; single mutants are viable and tumor-prone — a useful vascular/angiogenesis model given the BRRS vascular phenotype.
• Drosophila (NCBITaxon:7227): Pten mutants show classic cell-size and organ-size overgrowth; the system where the PI3K–TOR growth-control logic was largely worked out.
• C. elegans (NCBITaxon:6239): daf-18, the insulin/IGF-1–DAF-16 axis.
• Cell and in vitro: patient-derived fibroblasts and LCLs; patient iPSC-derived neurons and cortical organoids show increased soma size, altered proliferation, and synaptic phenotypes, and are the most translationally relevant human system currently available; CRISPR-edited isogenic lines (the route used for the TTN p.Cys5096Arg functional work). MorPhiC has not, to my knowledge, targeted PTEN — worth checking morphic.bio before asserting either way.

Recapitulation and limitations

Recapitulates well: macrocephaly/megalencephaly, neuronal soma enlargement, Lhermitte–Duclos-like cerebellar pathology, ASD-like social deficits, seizures, multi-organ tumor predisposition, enhanced insulin sensitivity.

Does NOT recapitulate: genital lentiginosis (no analog), the human GI mixed-polyp spectrum in its full form, the specific human cancer-organ distribution (mouse tumor spectrum skews differently — thyroid/endometrial/lymphoid rather than breast-dominant), PTEN hamartoma of soft tissue as a defined entity, and the human developmental/cognitive profile in any fine-grained way. Mouse background strain strongly modifies tumor spectrum. Any curated evidence item drawn from these should carry evidence_source: MODEL_ORGANISM and must not be the sole support for a human phenotype — and given the m3m4 findings are load-bearing for the ASD mechanism but unconfirmed in human tissue, a discussions entry with kind: HUMAN_MODEL_MISMATCH is warranted rather than a plain KNOWLEDGE_GAP.

Model databases

MGI (mouse), Alliance of Genome Resources, IMPC/KOMP, IMSR/JAX for strain availability, ZFIN, FlyBase, WormBase, Cellosaurus for lines.

Appendix A — Suggested mechanistic_hypotheses and discussions

Things I'd flag as genuinely unsettled, worth curating as structured discussion rather than prose:

1. nuclear_vs_cytoplasmic_pten (competing hypothesis groups). Whether the ASD/neurodevelopmental arm is driven by loss of nuclear PTEN function (DNA repair, m3m4 evidence) versus by cytoplasmic PIP₃/mTORC1 excess. status: EMERGING. Attaches to the neurodevelopmental branch.
2. ttn_as_brrs_gene — KNOWLEDGE_GAP / EMERGING. TTN enrichment in PTEN-wildtype BRRS is statistically modest (OR 2.2–2.7, p ≈ 0.02–0.05, single lab, no replication cohort published that I found). Do not curate TTN as causal.
3. phts_penetrance_ascertainment — KNOWLEDGE_GAP. Clinic-ascertained lifetime cancer risks (breast 85%) versus biobank-derived risks (54–76%, and much lower overall penetrance in All of Us/UK Biobank) differ enough to change clinical advice. Unresolved.
4. mtor_inhibition_efficacy — KNOWLEDGE_GAP. Sirolimus pilots are positive on biomarkers and lesions; the only randomized everolimus trial missed its neurocognitive primary endpoint. Whether mTOR inhibition helps any PHTS outcome durably is open.
5. hashimoto_thyroiditis_mechanism — KNOWLEDGE_GAP. Autoimmune thyroiditis is overrepresented since Gorlin 1992; no mechanism connects PTEN loss to thyroid autoimmunity.
6. brrs_cowden_entity_boundary. Worth an explicit note: this KB models BRRS and Cowden as separate entries while the literature treats them as one disease. Consider a Grouping over the PHTS entries with grouping_basis: [SHARED_MECHANISM, CLINICAL_CONVENTION] and a grouping_rationale that records exactly this lump/split tension — a NECESSARY HAS_GENE criterion on PTEN would make the boundary auditable.

Appendix B — Suggested conforms_to module targets

Check these against kb/modules/ before asserting: - The PI3K–AKT–mTOR overgrowth logic here has no dedicated module yet — BRRS/PHTS would be a strong flagship if one is created (candidate: pi3k_akt_mtor_overgrowth). - genome_instability_mutation — the nuclear-PTEN/RAD51 arm plausibly conforms. - sustaining_proliferative_signaling — constitutive PI3K–AKT mitogenic signaling is exactly this hallmark node. - evading_growth_suppressors — PTEN is a canonical tumor suppressor; the two-hit/haploinsufficiency logic fits. - tumor_angiogenesis — for the vascular malformation arm, though the fit is imperfect (these are malformations, not tumor neovasculature).

References (with PMIDs)

Verbatim abstract text retrieved and usable as evidence snippets (still run just fetch-reference + just validate-references):

• PMID:10400993 — Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999;8(8):1461-72. doi:10.1093/hmg/8.8.1461
• PMID:9467011 — Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome. Hum Mol Genet. 1998;7(3):507-15. doi:10.1093/hmg/7.3.507
• PMID:22252256 — Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400-7.
• PMID:20600018 — Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010;139(6):1927-33.
• PMID:22446940 — Kurek KC, Howard E, Tennant LB, et al. PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes. Am J Surg Pathol. 2012;36(5):671-87.
• PMID:29263846 — Yehia L, Ni Y, Eng C. Germline TTN variants are enriched in PTEN-wildtype Bannayan-Riley-Ruvalcaba syndrome. npj Genom Med. 2017;2:37. doi:10.1038/s41525-017-0039-y
• PMID:31609537 — Macken WL, Tischkowitz M, Lachlan KL. PTEN hamartoma tumor syndrome in childhood: A review of the clinical literature. Am J Med Genet C. 2019.
• PMID:39256443 — Kapačinskaitė M, Stratica N, Adomaitienė I, Rascon J, Vaišnytė B. A systematic review of Bannayan-Riley-Ruvalcaba syndrome. Sci Rep. 2024;14. doi:10.1038/s41598-024-71991-2

Cited but abstract not independently retrieved verbatim — verify before quoting:

• PMID:9241266 — Marsh DJ, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet. 1997;16(4):333-4. ⚠️ Letter — no abstract exists. Cannot supply a snippet.
• PMID:11332402 — Parisi MA, et al. The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan-Riley-Ruvalcaba syndrome. J Med Genet. 2001;38(1):52-8. ⚠️ No abstractText in Europe PMC; use PMC1734718 full text.
• PMID:1336932 — Gorlin RJ, et al. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet. 1992;44(3):307-14.
• PMID:9593664 — Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273(22):13375-8.
• PMID:12938083 — Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003.
• PMID:11726927 / PMID:11726928 — Backman SA et al.; Kwon CH et al. Nat Genet. 2001.
• PMID:16675393 — Kwon CH, Luikart BW, Powell CM, et al. Pten regulates neuronal arborization and social interaction in mice. Neuron. 2006;50(3):377-88.
• PMID:18678321 — Ni Y, Zbuk KM, Sadler T, et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet. 2008;83(2):261-8.
• PMID:21177507 — Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA. 2010;304(24):2724-31.
• PMID:25288137 — Frazier TW, et al. Molecular and phenotypic abnormalities in individuals with germline heterozygous PTEN mutations and autism. Mol Psychiatry. 2015.
• PMID:25754085 — Neural transcriptome of constitutional Pten dysfunction in mice and its relevance to human idiopathic ASD.
• PMID:23907246 — Bhargava R, et al. Bannayan-Riley-Ruvalcaba syndrome: MRI neuroimaging features in a series of 7 patients. AJNR. 2014;35(2):402.
• PMID:35594551 — Srivastava S, et al. A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. Hum Mol Genet. 2022;31(20):3393-404.
• PMID:39250745 — Dhawan A, Baitamouni S, Liu D, Eng C. Clinical Neurologic Features and Evaluation of PTEN Hamartoma Tumor Syndrome: A Systematic Review. Neurology. 2024;103(7):e209844.
• PMID:31433955 — Yehia L, Keel E, Eng C. The Clinical Spectrum of PTEN Mutations. Annu Rev Med. 2020.
• Tischkowitz M, Colas C, Pouwels S, et al. Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. Eur J Hum Genet. 2020;28:1387-93. (PMC7608293)
• Komiya T, Blumenthal GM, DeChowdhury R, et al. A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN. The Oncologist. 2019;24(12):1510. (PMC6975943)
• Hendricks LAJ, et al. A review on age-related cancer risks in PTEN hamartoma tumor syndrome. Clin Genet. 2021. (PMC7839546) · Cancer risks by sex and variant type in PHTS. JNCI. 2023.
• Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex. Clin Cancer Res. 2025;31(2):234.
• PMID:41480035 — Population-based Characterization of PTEN Hamartoma Tumor Syndrome. medRxiv preprint, Dec 2025 — cite as preliminary.
• Sarn N, et al. Cytoplasmic-predominant Pten increases microglial activation and synaptic pruning in a murine model with autism-like phenotype. Mol Psychiatry. 2021. (PMC8159731)
• GeneReviews: PTEN Hamartoma Tumor Syndrome. NCBI Bookshelf NBK1488. (PMID:20301661)

Sources:

• PTEN Hamartoma Tumor Syndrome — GeneReviews (NBK1488)
• MONDO:0007924 — EBI OLS4
• A systematic review of Bannayan–Riley–Ruvalcaba syndrome (PMC11387762)
• Marsh 1999, PTEN mutation spectrum in BRRS (PMID:10400993)
• Germline TTN variants in PTEN-wildtype BRRS (PMID:29263846)
• Tan 2012, Lifetime cancer risks in germline PTEN mutations (PMID:22252256)
• Heald 2010, GI polyps in PTEN mutation carriers (PMID:20600018)
• Kurek 2012, PTEN hamartoma of soft tissue (PMID:22446940)
• Macken 2019, PHTS in childhood (PMID:31609537)
• Cancer Surveillance Guideline for PHTS (PMC7608293)
• Update on Pediatric Surveillance Recommendations, Clin Cancer Res 2025
• Everolimus RCT for neurocognitive symptoms in PHTS (PMID:35594551)
• Sirolimus pilot in Cowden syndrome (PMC6975943)
• German pediatric PHTS guideline (PMC8859017)
• Population-based Characterization of PHTS — preprint (PMC12755263)
• Clinical Neurologic Features of PHTS, Neurology 2024
• Cytoplasmic-predominant Pten / microglial pruning (PMC8159731)
• Maehama & Dixon 1998, PTEN dephosphorylates PIP3 (PMID:9593664)
• Kwon 2006, Pten regulates neuronal arborization and social interaction (PMID:16675393)
• Ni 2008, SDH variants in Cowden/Cowden-like (PMID:18678321)
• Germline epigenetic regulation of KILLIN (PMID:21177507)
• Orphanet: Bannayan-Riley-Ruvalcaba syndrome (ORPHA:109)
• NORD: Bannayan-Riley-Ruvalcaba Syndrome
• MedGen C0265326